• Skip to primary navigation
  • Skip to main content
  • Skip to footer
ARVC Studies

ARVC Studies

  • About ARVC
    • Overview
    • Causes
    • Symptoms
    • Diagnosis
  • Gene Therapy for ARVC
    • Basic Genetics
    • Mutations & Disease
    • Gene Therapy
    • AAV Capsids
    • TN-401 for ARVC
  • Our Studies
    • RIDGE-1
    • RIDGE
  • Resources
  • Contact Us
Our StudiesRIDGE

Share this page:

For more information about Tenaya’s clinical programs, complete this form or contact Wendy on our Patient Advocacy team by email or phone at (650) 825-6990 option 4.

Wendy Borsari, Associate Director of Patient Advocacy, Living with genetic HCM, community advocate for over a decade

RIDGE:

An Antibody Testing and Observational Study

RIDGETM is an antibody testing and observational study designed to learn about the levels of AAV antibodies in people with ARVC caused by a PKP2 mutation. It is also designed to provide valuable information about who might be eligible for and benefit from an AAV-based gene therapy such as TN-401.

Who can take part in the RIDGE study?

People between the ages of 14 – 65 who have the PKP2 gene mutation with a diagnosis of ARVC.

Study staff will evaluate people interested in taking part in RIDGE and determine if they are eligible. These are not all of the eligibility criteria for this study. 

What is the purpose of the RIDGE study?

This study has been carefully designed to collect data such as people’s medical information, family history, and other related information that will provide researchers with more information about the condition and the PKP2 genetic mutation. The RIDGE study is an antibody testing and observational study that will enroll approximately 200 participants at about 30 sites worldwide.

What to expect in the RIDGE study?

During the five-year study, researchers will gather data to help evaluate the disease course, burden of illness, risk factors, and biomarkers (measurable characteristics of ARVC such as protein levels in the blood) associated with disease progression.   

Two types of information will be gathered for each participant:

Prospective
(collected during participant visits)

Data will be collected during the participant’s usual visits to the study doctor’s office from time of enrollment for up to 5 years.

Retrospective
(collected from medical chart information)

Information that has already been collected as part of past doctor’s visits. This study will look at data in medical charts collected up to 10 years ago.

For the prospective part of the study, data will be collected as part of regularly planned doctor visits and recorded by a cardiologist or nurse.

These visits will include the typical tests that are conducted as part of a regular office visit, with additional study-related activities, such as:

Filling out quality-of-life questionnaires (surveys) throughout the study

The surveys may include questions about heart health, emotional and physical wellbeing, and how often a person may feel a certain way.

Blood tests to learn about the levels of AAV antibodies in people with ARVC with a PKP2 mutation

The study will not require any extra visits with a participant’s doctor. Participation is entirely voluntary, and participants are free to leave the study at any time without impact to routine care.

Participation in the RIDGE study is entirely voluntary. There is no cost to participate in this study.

Study locations

The RIDGE study is being conducted in leading cardiovascular research centers in North America and Europe.

United States Locations

California Locations

San Francisco, California, United States, 94143

Recruiting

University of California San Francisco

Contact: Vasanth Vedantham, MD, PhD

Colorado Locations

Aurora, Colorado, United States, 80045

Recruiting

University of Colorado, Denver

Contact: Matthew Taylor, MD, PhD

Maryland Locations

Baltimore, Maryland, United States, 21287

Recruiting

John Hopkins University School of Medicine

Contact: Hugh G Calkins, MD

Massachusetts Locations

Boston, Massachusetts, United States, 02115

Recruiting

Brigham and Women's Hospital

Contact: Neal Lakdawala, MD

Minnesota Locations

Rochester, Minnesota, United States, 55905

Recruiting

Mayo Clinic

Contact: John Giudicessi, MD PhD

New York Locations

New York, New York, United States, 10016

Recruiting

New York University

Contact: Larry Chinitz, MD

Ohio Locations

Cleveland, Ohio, United States, 44195

Recruiting

Cleveland Clinic

Contact: Wai Hong Wilson Tang, MD

South Carolina Locations

Charleston, South Carolina, United States, 29425

Recruiting

Medical University of South Carolina

Contact: Daniel Judge, MD

France Locations

Bron, France,

Recruiting

Hopital Louis Pradel

Contact: Philippe Chevalier, MD, PhD

Nantes, France, 44000

Recruiting

Nantes University Hospital

Contact: Vincent Probst, MD

Paris, France, 75013

Recruiting

Pitié-Salpêtrière Hospital

Contact: Estelle Gandjbakhch, MD, PhD

Pessac, France, 33604

Recruiting

Hôpital Haut-Lévêque

Contact: Frederic Sacher, MD, PhD

Germany Locations

Münster, Germany, 48149

Recruiting

University Hospital Muenster

Contact: Eric Schulze-Bahr, MD

Würzburg, Germany, 97080

Recruiting

Wuerzburg University Hospital

Contact: Brenda Gerull, MD

Italy Locations

Milano, Italy, 20138

Recruiting

Centro Cardiologico Monzino

Contact: Claudio Tondo, MD

Pavia, Italy,

Recruiting

Istituti Clinici Scientifici Maugeri SpA

Contact: Silvia Priori, MD, PhD

Sweden Locations

Malmö, Sweden, 214 28

Recruiting

Skåne University Hospital

Contact: Pyotr G Platonov, MD

United Kingdom Locations

Glasgow, United Kingdom, G514TF

Recruiting

The Queen Elizabeth Hospital

Contact: Caroline Coats, MD

London, United Kingdom, E1 1BB

Recruiting

Barts & The London Health NHS Trust

Contact: Perry Elliott, MD

London, United Kingdom, SW17 0QT

Recruiting

St. George's University Hospitals NHS Foundation Trust

Contact: Elijah Behr, MD

London, United Kingdom, SW3 6NP

Recruiting

Royal Brompton & Harefield NHS Foundation Trust

Contact: Antonio Pantazis, MD

Scroll to see more locations

If you are interested in participating:

Talk to your doctor about whether you may be a candidate for this study

  • Visit ClinicalTrials.gov (NCT06311708) to learn more

Complete this form or contact clinical.trials@tenayathera.com or patient.advocacy@tenayathera.com to request more information

Complete the form

Footer

  • X formerly twitter
  • LinkedIn
  • Facebook
  • Instagram

This website is a service of Tenaya Therapeutics, Inc., a clinical-stage biotechnology company committed to a bold mission: to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease.

  • Expanded Access Policy
  • Privacy Policy
  • Cookie Policy
  • Terms & Conditions
  • Community Guidelines

© 2024 Tenaya Therapeutics. All rights reserved
Last Updated November 25, 2024